Cocrystal Pharma Inc. has reported the discovery of direct-acting antivirals that demonstrate pan-viral activity against multiple viruses, including hantavirus, bunyavirus and influenza. These compounds target a highly conserved region of the viral replication enzyme – the L-protein of Andes virus, which is essential for viral replication and transcription.